NCT04396886View on ClinicalTrials.gov

Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 27, 2020

Primary Completion Date

September 30, 2022

Study Completion Date

July 26, 2023

Conditions
Nasopharyngeal CarcinomaRecurrent CarcinomaMetastatic CancerNon-keratinizing Carinoma
Interventions
DRUG

Bintrafusp Alfa

Bintrafusp alfa will be administered intravenously every 2 weeks

Trial Locations (1)

Unknown

Queen Mary Hospital, Hong Kong

All Listed Sponsors
collaborator

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

The University of Hong Kong

OTHER

NCT04396886 - Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC | Biotech Hunter | Biotech Hunter